China's strengthening intellectual property (IP) protection is boosting confidence of multinational companies.
AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai.
China could be "a jurisdiction of first resort to commence any IP enforcement actions," said Wang Rongxia, the pharma giant's legal director.
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.